Patent intelligence · US
US 7244448
Liposomal antineoplastic drugs and uses thereof
Liposomal antineoplastic drugs and uses thereof
Patent details — US 7244448
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 17, 2007
- Expiration
- Jul 12, 2027
- Applicant
- Tekmira Pharmaceuticals Corporation
- Claims
- 5
- CPC classes
- A61K, A61K31/4745, A61K45/06, A61K9/127
Quick answer
US 7244448 (Liposomal antineoplastic drugs and uses thereof) is held by Tekmira Pharmaceuticals Corporation. Status: granted. Granted Jul 17, 2007. Expires Jul 12, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tekmira Pharmaceuticals Corporation
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/4745, A61K45/06, A61K9/127, A61K9/1272, A61K9/1278
More from Tekmira Pharmaceuticals Corporation
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 7244448?
US 7244448 (Liposomal antineoplastic drugs and uses thereof) is held by Tekmira Pharmaceuticals Corporation. Status: granted. Granted Jul 17, 2007. Expires Jul 12, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7244448?
Tekmira Pharmaceuticals Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 7244448 expire?
Our index shows an expiration date of Jul 12, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.